Literature DB >> 22622948

Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

Konstantinos N Fountoulakis1, Siegfried Kasper, Ole Andreassen, Pierre Blier, Ahmed Okasha, Emanuel Severus, Marcio Versiani, Rajiv Tandon, Hans-Jürgen Möller, Eduard Vieta.   

Abstract

The current statement is a systematic review of the available data concerning the efficacy of medication treatment of bipolar disorder (BP). A systematic MEDLINE search was made concerning the treatment of BP (RCTs) with the names of treatment options as keywords. The search was updated on 10 March 2012. The literature suggests that lithium, first and second generation antipsychotics and valproate and carbamazepine are efficacious in the treatment of acute mania. Quetiapine and the olanzapine-fluoxetine combination are also efficacious for treating bipolar depression. Antidepressants should only be used in combination with an antimanic agent, because they can induce switching to mania/hypomania/mixed states/rapid cycling when utilized as monotherapy. Lithium, olanzapine, quetiapine and aripiprazole are efficacious during the maintenance phase. Lamotrigine is efficacious in the prevention of depression, and it remains to be clarified whether it is also efficacious for mania. There is some evidence on the efficacy of psychosocial interventions as an adjunctive treatment to medication. Electroconvulsive therapy is an option for refractory patients. In acute manic patients who are partial responders to lithium/valproate/carbamazepine, adding an antipsychotic is a reasonable choice. The combination with best data in acute bipolar depression is lithium plus lamotrigine. Patients stabilized on combination treatment might do worse if shifted to monotherapy during maintenance, and patients could benefit with add-on treatment with olanzapine, valproate, an antidepressant, or lamotrigine, depending on the index acute phase. A variety of treatment options for BP are available today, but still unmet needs are huge. Combination therapy may improve the treatment outcome but it also carries more side-effect burden. Further research is necessary as well as the development of better guidelines and algorithms for the step-by-step rational treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22622948     DOI: 10.1007/s00406-012-0323-x

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  550 in total

1.  Decreasing national suicide rates--fact or fiction?

Authors:  Zoltán Rihmer
Journal:  World J Biol Psychiatry       Date:  2004-01       Impact factor: 4.132

Review 2.  Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy.

Authors:  L A Smith; V Cornelius; A Warnock; M J Tacchi; D Taylor
Journal:  Acta Psychiatr Scand       Date:  2007-01       Impact factor: 6.392

3.  Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder.

Authors:  Paul E Keck; Jim Mintz; Susan L McElroy; Marlene P Freeman; Trisha Suppes; Mark A Frye; Lori L Altshuler; Ralph Kupka; Willem A Nolen; Gabriele S Leverich; Kirk D Denicoff; Heinz Grunze; Naihua Duan; Robert M Post
Journal:  Biol Psychiatry       Date:  2006-06-30       Impact factor: 13.382

Review 4.  Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder 2000.

Authors:  Trisha Suppes; Ellen B Dennehy; Alan C Swann; Charles L Bowden; Joseph R Calabrese; Robert M A Hirschfeld; Paul E Keck; Gary S Sachs; M Lynn Crismon; Marcia G Toprac; Steven P Shon
Journal:  J Clin Psychiatry       Date:  2002-04       Impact factor: 4.384

5.  The effectiveness of cognitive behavioral group therapy in treating bipolar disorder: a randomized controlled study.

Authors:  Rafael Thomaz da Costa; Elie Cheniaux; Pedro Augusto Legnani Rosaes; Marcele Regine de Carvalho; Rafael Christophe da Rocha Freire; Márcio Versiani; Bernard Pimentel Rangé; Antonio Egidio Nardi
Journal:  Braz J Psychiatry       Date:  2011-06       Impact factor: 2.697

6.  Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder.

Authors:  Chih-Chiang Chiu; Shih-Yi Huang; Chiao-Chicy Chen; Kuan-Pin Su
Journal:  J Clin Psychiatry       Date:  2005-12       Impact factor: 4.384

7.  Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine.

Authors:  Mauricio Tohen; Joseph R Calabrese; Gary S Sachs; Michael D Banov; Holland C Detke; Richard Risser; Robert W Baker; James C-Y Chou; Charles L Bowden
Journal:  Am J Psychiatry       Date:  2006-02       Impact factor: 18.112

Review 8.  Is anticonvulsant treatment of mania a class effect? Data from randomized clinical trials.

Authors:  A R Rosa; K Fountoulakis; M Siamouli; X Gonda; E Vieta
Journal:  CNS Neurosci Ther       Date:  2009-12-15       Impact factor: 5.243

9.  Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.

Authors:  Mauricio Tohen; Eduard Vieta; Joseph Calabrese; Terence A Ketter; Gary Sachs; Charles Bowden; Philip B Mitchell; Franca Centorrino; Richard Risser; Robert W Baker; Angela R Evans; Karin Beymer; Sanjay Dube; Gary D Tollefson; Alan Breier
Journal:  Arch Gen Psychiatry       Date:  2003-11

10.  A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness.

Authors:  T Okuma; K Inanaga; S Otsuki; K Sarai; R Takahashi; H Hazama; A Mori; S Watanabe
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

View more
  34 in total

1.  Evaluation of left ventricular systolic and diastolic functions in bipolar patients during lithium therapy.

Authors:  Cemil Zencir; Filiz A Ozdemiroglu; Mustafa Cetin; Sibel N Avcil; Mithat Selvi; Hasan Gungor; Cagdas Akgullu; Ebru Findikli; Gurkan Acar
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Fenproporex increases locomotor activity and alters energy metabolism, and mood stabilizers reverse these changes: a proposal for a new animal model of mania.

Authors:  Gislaine T Rezin; Camila B Furlanetto; Giselli Scaini; Samira S Valvassori; Cinara L Gonçalves; Gabriela K Ferreira; Isabela C Jeremias; Wilson R Resende; Mariane R Cardoso; Roger B Varela; João Quevedo; Emilio L Streck
Journal:  Mol Neurobiol       Date:  2013-10-15       Impact factor: 5.590

Review 3.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

4.  Antipsychotic-like effects of a neurotensin receptor type 1 agonist.

Authors:  Chelsea A Vadnie; Jennifer Ayers-Ringler; Alfredo Oliveros; Osama A Abulseoud; Sun Choi; Mario J Hitschfeld; Doo-Sup Choi
Journal:  Behav Brain Res       Date:  2016-02-22       Impact factor: 3.332

5.  Acute interventions and referral of patients with bipolar disorder by the psychiatric consultation liaison service in a general hospital in Germany: a retrospective analysis.

Authors:  Christina Anderson; Arnim Quante
Journal:  Prim Care Companion CNS Disord       Date:  2014-04-03

6.  The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management.

Authors:  Angel L Montejo; Laura Montejo; David S Baldwin
Journal:  World Psychiatry       Date:  2018-02       Impact factor: 49.548

7.  Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid.

Authors:  F Calabrese; A Luoni; G Guidotti; G Racagni; F Fumagalli; M A Riva
Journal:  Psychopharmacology (Berl)       Date:  2012-10-24       Impact factor: 4.530

Review 8.  Mania: diagnosis and treatment recommendations.

Authors:  Gin S Malhi; Michelle Tanious; Michael Berk
Journal:  Curr Psychiatry Rep       Date:  2012-12       Impact factor: 5.285

9.  Adjunctive Methylphenidate in the Treatment of Bulimia Nervosa Co-occurring with Bipolar Disorder and Substance Dependence.

Authors:  Anna I Guerdjikova; Susan L McElroy
Journal:  Innov Clin Neurosci       Date:  2013-02

10.  Ebselen has lithium-like effects on central 5-HT2A receptor function.

Authors:  I Antoniadou; M Kouskou; T Arsiwala; N Singh; S R Vasudevan; T Fowler; E Cadirci; G C Churchill; T Sharp
Journal:  Br J Pharmacol       Date:  2018-05-22       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.